To investigate how XUC treatment inhibited tumor progression, we conducted Ki67 immunohistochemistry (IHC) and TUNEL assays to further assess the cellular effects of the antitumor efficacy by XUC treatment on the NMIBC bladder tumors. Here, MKI67 is linked to urinary bladder neoplasm.